Esperion Therapeutics Inc (ESPR) concluded trading on Wednesday at a closing price of $0.95, with 4.92 million shares of worth about $4.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.47% during that period and on April 23, 2025 the price saw a gain of about 2.10%. Currently the company’s common shares owned by public are about 195.85M shares, out of which, 194.37M shares are available for trading.
Stock saw a price change of -4.67% in past 5 days and over the past one month there was a price change of -45.45%. Year-to-date (YTD), ESPR shares are showing a performance of -56.85% which decreased to -51.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.82 but also hit the highest price of $3.94 during that period. The average intraday trading volume for Esperion Therapeutics Inc shares is 4.52 million. The stock is currently trading -18.97% below its 20-day simple moving average (SMA20), while that difference is down -36.11% for SMA50 and it goes to -52.16% lower than SMA200.
Esperion Therapeutics Inc (NASDAQ: ESPR) currently have 195.85M outstanding shares and institutions hold larger chunk of about 58.81% of that.
The stock has a current market capitalization of $188.08M and its 3Y-monthly beta is at 0.85. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 11.28% while standing at 9.08% over the month.
Stock’s fiscal year EPS is expected to rise by 87.00% while it is estimated to decrease by -481.51% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 18, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by Cantor Fitzgerald stated Esperion Therapeutics Inc (ESPR) stock as an Overweight in their note to investors on December 17, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from JP Morgan on November 20, 2023.
